WE CAN MEDICINES CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 72 TWD | +0.56% |
|
+0.70% | -33.33% |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 3,796 | 4,320 |
| Enterprise Value (EV) 1 | 4,637 | 5,476 |
| P/E ratio | 39.5 x | 309 x |
| Yield | - | 0.28% |
| Capitalization / Revenue | 1.15 x | 1.38 x |
| EV / Revenue | 1.4 x | 1.75 x |
| EV / EBITDA | 26.4 x | 64.5 x |
| EV / FCF | 32,674,452 x | -1,950,597,622 x |
| FCF Yield | 0% | -0% |
| Price to Book | 4.79 x | 5.29 x |
| Nbr of stocks (in thousands) | 40,000 | 40,000 |
| Reference price 2 | 94.90 | 108.0 |
| Announcement Date | 23-03-03 | 24-03-01 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales 1 | 2,667 | 2,794 | 3,303 | 3,123 |
| EBITDA 1 | 71.15 | 76.28 | 175.5 | 84.94 |
| EBIT 1 | 34.64 | 30.33 | 117.2 | 23.94 |
| Operating Margin | 1.3% | 1.09% | 3.55% | 0.77% |
| Earnings before Tax (EBT) 1 | 42.71 | 38.79 | 121.1 | 21.6 |
| Net income 1 | 42.71 | 38.79 | 100.1 | 14.8 |
| Net margin | 1.6% | 1.39% | 3.03% | 0.47% |
| EPS 2 | 1.330 | 0.9698 | 2.400 | 0.3500 |
| Free Cash Flow | - | -72.62 | 141.9 | -2.807 |
| FCF margin | - | -2.6% | 4.3% | -0.09% |
| FCF Conversion (EBITDA) | - | - | 80.88% | - |
| FCF Conversion (Net income) | - | - | 141.84% | - |
| Dividend per Share | - | - | - | 0.3000 |
| Announcement Date | 22-10-26 | 22-10-26 | 23-03-03 | 24-03-01 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | 387 | 687 | 841 | 1,156 |
| Net Cash position 1 | - | - | - | - |
| Leverage (Debt/EBITDA) | 5.436 x | 9.013 x | 4.793 x | 13.61 x |
| Free Cash Flow | - | -72.6 | 142 | -2.81 |
| ROE (net income / shareholders' equity) | - | 5.83% | 13.6% | 1.84% |
| ROA (Net income/ Total Assets) | - | 0.95% | 3.06% | 0.55% |
| Assets 1 | - | 4,070 | 3,269 | 2,689 |
| Book Value Per Share 2 | 20.10 | 17.10 | 19.80 | 20.40 |
| Cash Flow per Share 2 | 3.750 | 5.080 | 5.410 | 4.010 |
| Capex 1 | 58 | 340 | 123 | 92.6 |
| Capex / Sales | 2.17% | 12.15% | 3.71% | 2.96% |
| Announcement Date | 22-10-26 | 22-10-26 | 23-03-03 | 24-03-01 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -33.33% | 97.87M | |
| -23.37% | 3.23B | |
| -12.69% | 2.88B | |
| -28.84% | 2.8B | |
| +11.41% | 2.68B | |
| +11.05% | 2.63B | |
| +8.48% | 1.33B | |
| -21.75% | 959M | |
| -37.64% | 745M | |
| -0.53% | 456M |
- Stock Market
- Equities
- 6929 Stock
- Financials We Can Medicines Co., Ltd.
